Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kabirullah Lutfy has a total of 150 co-authors. Here are the top co-authors by number of shared publications:

  • Abdul Hamid

    Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences

    17 shared publications
  • Paul Marquez

    Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA

    14 shared publications
  • Syed Muzzammil Ahmad

    Department of Biomedical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA

    8 shared publications
  • Abdul Hamid

    Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA

    7 shared publications
  • Shafiqur Rahman

    Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, South Dakota

    7 shared publications
  • Theodore C. Friedman

    Division of Endocrinology, Metabolism and Molecular Medicine, Charles R. Drew University of Medicine and Science and David Geffen School of Medicine at UCLA, Los Angeles, CA (J.W., P.W., R.P., S.K., X.M.S., T.C.F., Y.L.).

    6 shared publications

Latest Publications

  • Open Access

    A mouse model of oxycodone reward following its oral self-administration in a sweetened solution

    by Shayesteh Rounama, Prince Meziem, Abdul Hamid, Iffat H. Era, Kabirullah Lutfy

    Introduction: This study aimed to develop a preclinical model in which reinforcement and reward can be measured in the same subject. To this end, we combined the power of drug self-administration and place conditioning paradigms and determined whether voluntary oral oxycodone self-administration would induce conditioned place preference (CPP) and whether this response could be extinguished and reinstated. To assess the face validity of the model, we also evaluated the role of the mu-opioid receptor (MOP) in this process. Methods: Male and female C57BL/6 mice, as well as male MOP knockout mice and their wild-type littermates, were initially conditioned with sucrose (4%) in both conditioning chambers for 1 h daily for 2 weeks (4 days a week). Mice were then tested for basal place preference and then underwent alternate-day conditioning (1 h daily) with sucrose (4%) in one chamber and oxycodone in a 4% sucrose solution in the opposite chamber the following day for four consecutive days, followed by a CPP test. The following week, another set of conditioning and testing for CPP was repeated. Subsequently, mice were exposed to the sucrose (45) solution alone for 4 days each week, and a test for extinction of the CPP response at the end of each week. After extinction, mice were challenged with oxycodone (5 mg/kg) and tested for the reinstatement of CPP. Results: Both male and female mice demonstrated robust voluntary oral oxycodone self-administration in a 4% sucrose solution, but it was lower in females than in males. Oxycodone self-administration was associated with CPP in male and female mice. This response was extinguished and reinstated. Unlike wild-type mice, the CPP response was not observed in mice lacking MOP, suggesting that MOP is involved in this response. Discussion: This is the first study providing evidence for the development of a translational mouse model of reward utilizing oral oxycodone self-administration in a sweetened solution.

  • Open Access

    Editorial: Exploring the interplay between stress, neuropeptides, and alcohol use disorder

    by Kabirullah Lutfy, Marcelo López

    Alcohol use disorders (AUD) are major public health issues, with a significant negative impact on the health system and the economy. Unfortunately, only a handful of pharmacotherapeutic agents are available to treat patients with AUD. Notably, these medications have limited efficacy in reducing alcohol consumption, craving, and relapse. Therefore, there is a need for development of more effective medications to treat AUD. Preclinical studies as well as some clinical trials have shown that a series of neuropeptides, such as dynorphin, orexin, etc., as well as peptides released from the periphery and acting centrally, such as glucagon-like peptide, amylin, and ghrelin, have shown promise to alter alcohol self-administration, signs of withdrawal, and relapse. These peptides also show promise in reducing stress-mediated craving and relapse, which is a central issue in treating alcohol use disorders. In this special topic series, Holguin and Martin-Fardon provide a review of the literature on the interaction between orexin (OX) and dynorphin (DYN) in the posterior paraventricular nucleus of thalamus (pPVT) and postulate that this interaction may underly the stress-mediated craving and relapse after chronic alcohol use. These authors also discuss the potential of targeting the receptors for each peptide to reduce stress-induced alcohol craving and relapse. They also propose that a deeper understanding of the balance between the two neuropeptide systems within the reward and stress circuits may unveil insights for relapse prevention in individuals with AUD. In an elegant study, Van Doorn, Jaramillo, and Tyree determined the role of calcitonin gene-related peptide in the parabrachial nucleus (PBN) in anxiety-like behaviors in mice undergoing abstinence, as the level of CGRP is elevated in alcoholdrinking and alcohol-preferring subjects. The authors focused on PBN as it contains high levels of CGRP. Calca-cre mice and Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) were used to assess the role of PBN CGRP in anxiety-like behaviors following alcohol withdrawal compared to naïve controls. The authors proposed that PBN CGRP may be a potential target to treat anxiety-like behaviors that develop following acute withdrawal. In another study, Francisco J Flores-Ramirez, Glenn Pascasio and Remi Martin-Fardon determined the role of DYN and OX in the pPVT in alcohol reinstatement using the operant conditioning paradigm. Rats were trained to self-administer a 10% ethanol solution for three weeks followed by a 6-week chronic intermittent alcohol vapor exposure. Rats underwent extinction training and then tested for stress-induced reinstatement of alcohol self-administration following local intra-pPVT OX or kappa opioid receptor (KOR) antagonist or their combination. While either antagonist reduced reinstatement of ethanol self-administration, their combination was not as effective. An increase in the level of both peptides was observed in the hypothalamus along with an increase in KOR gene (Oprk1) and decrease in OX receptor 1 gene (Hcrt1) were also observed in the pPVT, showing an interaction between the two peptides/receptor systems in the pPVT. The study by Zhao et al. adds relevant evidence on the effect of a history of alcohol consumption on stress reactivity. Using a model of voluntary alcohol intake in mice combined with a single prolonged stress procedure that results in PTSD-like symptoms, the study evaluates whether activation of cyclic adenosine monophosphate/protein kinase A (cAMP-PKA) pathway can be manipulated to attenuate the effects of alcohol on stress responsiveness. Their data show that activation of this pathway, which results in modulation of growth factors, represents a promising alternative to attenuating PTSDlike symptoms, particularly in subjects with a history of AUD. Overall, the articles included in this special issue offer new relevant evidence of the role of neuropeptides modulating circuitry associated with stress and negative affect that can help perpetuate problem drinking and/or relapse. Hopefully, this will foster further development in this area to evaluate promising new medications to treat AUD.

  • Open Access

    The Endogenous Opioid System in Compulsive Eating

    by Aneesha Janbandhu, Caden Leung, Evelyn Wu, Aidan Tom, Tobias D. Chang, Vinit Shah, Lauren Kim, Evan Robert Lauterborn, Kabirullah Lutfy

    Background/Objectives: The rates of obesity and binge-eating disorder (BED) have increased markedly over the last few decades. The onset of these conditions has been associated in part with the disruption of neural pathways that regulate food reward. Existing literature has implicated the endogenous opioid system as an important mediator of pleasure and reinforcing behaviors associated with food intake. While the relationship between opioids and food intake has been studied extensively, how dysregulated opioid signaling contributes to compulsive eating still remains unclear. Therefore, the aim of this review is to analyze the role of opioid peptides and receptors, and their interactions with dopamine in hedonic feeding. Methods: We conducted a narrative review of preclinical and clinical trials, incorporating studies that were relevant to opioid-mediated feeding and food reward. Results: β-endorphins appear to modulate the hedonic value of food, but their effects appear to be context-dependent. Enkephalins may influence motivational drive toward food, while nociceptin signaling has been linked to the preferential consumption of palatable foods under binge-like conditions. Consistent with these findings, NOP antagonism has been reported to reduce binge-like intake of a high-fat diet (HFD) without affecting homeostatic eating patterns. Lastly, chronic mu-opioid receptor (MOP) activation by palatable foods may induce neuroadaptive changes, including receptor desensitization, dopamine D2 receptor downregulation, and reward hypofunctionality, which overlap with mechanisms associated with substance use disorders. Conclusions: Altered MOP signaling may disrupt the hedonic and behavioral mechanisms that regulate feeding behavior. Pharmacological therapies targeting opioid and opioid-dopamine interactions may show promise for treating obesity and BED. However, additional research is still needed to clarify peptide-specific mechanisms, sex differences, and long-term neurobiological consequences associated with hedonic and compulsive eating.

  • Open Access

    The Endogenous Opioid System in Compulsive Eating

    by Aneesha Janbandhu, Caden Leung, Evelyn Wu, Aidan Tom, Tobias Chang, Vinit Shah, Lauren Kim, Evan Lauterborn, Kabirullah Lutfy

    Background/Objectives: The rates of obesity and binge-eating disorder (BED) have increased markedly over the last few decades. The onset of these conditions has been attributed in part to the disruption of neural pathways that regulate food reward. Existing literature has identified the endogenous opioid system as an important mediator of pleasure and reinforcing behaviors associated with food intake. While the relationship between opioids and food intake has been studied extensively, how dysregulated opioid signaling contributes to compulsive eating still remains unclear. Therefore, the aim of this review is to analyze the role of opioid peptides and receptors, and their interactions with dopamine in hedonic feeding. Methods: We conducted a narrative review of preclinical and clinical trials, incorporating studies that were relevant to opioid-mediated feeding and food reward. Results: β-endorphins modulate the hedonic value of food, but their effects appear to be context-dependent. Enkephalins regulate motivational drive toward food, while nociceptin signaling preferentially promotes the consumption of palatable foods under binge-like conditions. Consistent with these findings, NOP antagonism reduces binge on a high fat diet (HFD) without affecting homeostatic eating patterns. Lastly, chronic mu opioid receptor (MOR) activation by palatable foods may induce neuroadaptive changes, including receptor desensitization, dopamine D2 receptor downregulation, and reward hypofunctionality, paralleling mechanisms associated with substance use disorders. Conclusions: Altered MOR signaling disrupts the hedonic and behavioral mechanisms that regulate feeding behavior. Pharmacological therapies targeting opioid and opioid-dopamine interactions may show promise for treating obesity and BED. However, additional research is still needed to clarify peptide-specific mechanisms, sex differences, and long-term neurobiological consequences of hedonic and compulsive eating.

  • E-Cigarette Smoke Exposure Elevates Renal MR Expression and Induces BP Elevation

    by Jian Wang, Bei Xu, Ying Wang, Jenny Liu, Piwen Wang, Rene Porche, Samuel Kim, Rong Yang, Xuesi M. Shao, Kabirullah Lutfy, et al.

    BACKGROUND: E-cigarette use increases the risk of blood pressure (BP) elevation in users, though the underlying mechanisms remain unclear. The mineralocorticoid receptor (MR) is known to play an important role in the regulation of renal electrolyte balance and BP, and is protected by 11β-HSD2 (11β-hydroxysteroid dehydrogenase type 2). However, little is known about the effects of renal MR on e-cigarette-induced BP elevation. METHODS: C57BL/6J male mice were exposed to aerosolized PBS, e-cigarettes without nicotine, and e-cigarettes with 2.4% nicotine, with concurrent exposure to either a vehicle or the MR antagonist eplerenone. RESULTS: Inhalation of e-cigarettes with nicotine markedly induced renal MR abundance and increased mean arterial BP in response to elevated plasma nicotine levels in C57BL/6J mice. Induction of MR by e-cigarettes was correlated with a reduction in 11β-HSD2 and activation of pSer 9 GSK3β (glycogen synthase kinase-3β phosphorylation) within the kidneys. In contrast, e-cigarettes increased the urinary ratio of corticosterone to 11-dehydrocorticosterone, reduced urinary sodium content, and elevated renal epithelial sodium channel expression. However, inhaling e-cigarettes without nicotine did not affect these metabolic parameters. Treatment with eplerenone normalized BP, reversed urinary metabolic profiles, and reduced epithelial sodium channel by inhibiting renal pSer 9 GSK3β in nicotine e-cigarette-exposed mice. In mouse renal Cortical Collecting Duct (CCD) M1 cells, aerosol nicotine from e-cigarettes increased MR while decreasing 11β-HSD2, and these effects are likely via activation of pSer 9 GSK3β through a nicotinic receptor-mediated mechanism. CONCLUSIONS: Our findings highlight the potential renal health damage from e-cigarettes and suggest that aerosol nicotine-mediated induction of MR action in the kidneys may contribute to electronic smoking-induced BP elevation.

  • Open Access

    Dopamine D2 Receptors and Its Downstream Signaling in Compulsive Eating

    by Caden Leung, Kabirullah Lutfy

    Obesity has become a major public health crisis and serves as an underlying condition for other chronic metabolic diseases. The dysregulation of the inhibitory and regulatory mechanisms of the mesolimbic dopamine system, particularly dopamine D2 receptors (D2Rs), plays a critical role in driving excessive food consumption and compulsive eating habits. Based on the current literature, chronic consumption of high-fat foods elicits hedonic sensations and has the potential to downregulate and desensitize D2Rs, impairing their signaling and inhibitory action. This impairment thereby alters the downstream signaling of the D2Rs, involving the inhibition of adenylyl cyclase and the associated cascade. Although individual components of this proposed pathway have been studied, a comprehensive synthesis has not been established. This review aims to explore the relationship between D2R downregulation and desensitization and their effects on the downstream signaling cascade. We hypothesize that alterations in this pathway may lead to the dysregulation of the expression of orexigenic and anorexigenic neuropeptides, contributing to binge-eating behaviors.


  • Open Access

    Pituitary adenylyl cyclase-activating polypeptide modulates the stress response: the involvement of different brain areas and microglia

    by Anika Singh, Paul Shim, Sadaf Naeem, Shafiqur Rahman, Kabirullah Lutfy

    Stress is necessary for survival. However, chronic unnecessary stress exposure leads to cardiovascular, gastrointestinal and neuropsychiatric disorders. Thus, understanding the mechanisms involved in the initiation and maintenance of the stress response is essential since it may reveal the underpinning pathophysiology of these disorders and may aid in the development of medication to treat stress-mediated diseases. Pituitary adenylyl cyclase activating polypeptide (PACAP) and its receptors (PAC1, VPAC1 and VPAC2) are expressed in the hypothalamus and other brain areas as well as in the adrenal gland. Previous research has shown that this peptide/receptor system serves as a modulator of the stress response. In addition to modulating the stress response, this system may also be connected to its emerging role as neuroprotective against hypoxia, ischemia, and neurodegeneration. This article aims to review the literature regarding the role of PACAP and its receptors in the stress response, the involvement of different brain regions and microglia in PACAP-mediated modulation of the stress response, and the long-term adaptation to stress recognizable clinically as survival with resilience while manifested in anxiety, depression and other neurobehavioral disorders.


  • Open Access

    The Role of Endogenous Beta-Endorphin and Enkephalins in the Crosstalk Between Ethanol and Morphine

    by Andy Tseng, Syed Muzzammil Ahmad, Abdul Hamid, Kabirullah Lutfy

    Background: There is clinical concern about the combined use of alcohol and opiates. Several lines of evidence support an interaction between alcohol and the endogenous opioid system. Thus, we hypothesized that ethanol, by causing the release of opioid peptides, may sensitize the system to the action of exogenous opioids such as morphine. Objectives: In this study, using the place conditioning paradigm, a model of reward, we determined whether a morphine challenge would alter the pre-established preference induced by ethanol conditioning in mice, and whether this response was mediated by the mu opioid receptor (MOP). Given that ethanol exposure stimulates the release of opioid peptides, we also assessed the role of beta-endorphin (β-END) and enkephalins (ENKs) in this response. Methods: Mice lacking MOPs, β-END, and/or ENKs, and their respective wild-type controls were tested for preconditioning place preference on day 1. Mice were then conditioned with ethanol (2 g/kg) versus saline on days 2 to 4 and then tested under a drug-free state for postconditioning place preference on day 5. On day 8, mice received a single injection of morphine (5 mg/kg) and were tested for place preference. On the test days, mice were placed in the central chamber and allowed to explore the chambers. The amount of time that mice spent in the drug-paired chamber was recorded. Results: We found that a challenge dose of morphine given on day 8 enhanced the conditioned place preference (CPP) response in mice previously conditioned with ethanol. This response was abolished in MOP-null mice, confirming the role of MOPs in this response. Although this enhanced response was not altered in mice lacking either β-END or ENKs compared to their wild-type littermates/controls, it was completely blunted in mice lacking both β-END and enkephalins. Conclusions: Together, these results suggest that these opioid peptides jointly mediate the crosstalk between the rewarding actions of morphine and ethanol.


  • Open Access

    Challenges of Multidrug-Resistant Tuberculosis Meningitis: Current Treatments and the Role of Glutathione as an Adjunct Therapy

    by Mohammad J. Nasiri, Kabir Lutfy, Vishwanath Venketaraman

    Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health threat, especially when it involves the central nervous system (CNS). Tuberculous meningitis (TBM), a severe manifestation of TB, is linked to high mortality rates and long-term neurological complications, further exacerbated by drug resistance and immune evasion mechanisms employed by Mycobacterium tuberculosis (Mtb). Although pulmonary TB remains the primary focus of research, MDR-TBM introduces unique challenges in diagnosis, treatment, and patient outcomes. The effectiveness of current treatments is frequently compromised by poor CNS penetration of anti-TB drugs and the necessity for prolonged therapy, which often involves considerable toxicity. This review explores the potential of cytokine-based adjunct immunotherapies for MDR-TBM, addressing the challenges of balancing pro-inflammatory and anti-inflammatory signals within the CNS. A central focus is the prospective role of glutathione, not only in reducing oxidative stress but also in enhancing host immune defenses against Mtb’s immune evasion strategies. Furthermore, the development of vaccines aimed at upregulating glutathione synthesis in macrophages represents a promising strategy to bolster the immune response and improve treatment outcomes. By integrating glutathione and innovative vaccine approaches into MDR-TBM management, this review proposes a comprehensive strategy that targets Mtb directly while supporting immune modulation, with the potential to enhance patient outcomes and reduce treatment related adverse effects. We underscore the urgent need for further research into adjunctive therapies and immunomodulatory strategies to more effectively combat MDR-TBM.